Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 12, 2015, Pages 2140-2151

  Singal, Amit G ^a   El Serag, Hashem B ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chemoprevention; Cirrhosis; Hepatitis B; Hepatitis C; NAFLD; Surveillance

Indexed keywords

ADEFOVIR; ALCOHOL; ALPHA FETOPROTEIN; EMTRICITABINE; ENTECAVIR; HEPATITIS B VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; METFORMIN; PLACEBO; TENOFOVIR;

ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHRONIC HEPATITIS B; CLINICAL PRACTICE; COFFEE; COMPUTER ASSISTED TOMOGRAPHY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE SURVEILLANCE; DRUG EFFICACY; EARLY DIAGNOSIS; ECHOGRAPHY; HEPATITIS B; HEPATITIS C; HEREDITY; HIGH RISK PATIENT; HUMAN; LIFESTYLE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; VACCINATION; CARCINOMA, HEPATOCELLULAR; COMPLICATION; EARLY CANCER DIAGNOSIS; LIVER NEOPLASMS;

CARCINOMA, HEPATOCELLULAR; CHEMOPREVENTION; EARLY DETECTION OF CANCER; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS; RISK FACTORS;

EID: 84944392238     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.08.014     Document Type: Review

References (112)

1. El-Serag H.B. Hepatocellular carcinoma. N Engl J Med 2011, 365:1118-1127.
2. Njei B., Rotman Y., Ditah I., et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015, 61:191-199.
3. El-Serag H.B., Talwalkar J., Kim W.R. Efficacy, effectiveness, and comparative effectiveness in liver disease. Hepatology 2010, 52:403-407.
4. Kanwal F., El-Serag H.B. Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness. Clin Gastroenterol Hepatol 2014, 12:1381-1383.
5. Zapka J.G., Taplin S.H., Solberg L.I., et al. A framework for improving the quality of cancer care: the case of breast and cervical cancer screening. Cancer Epidemiol Biomarkers Prev 2003, 12:4-13.
6. Leyden W.A., Manos M.M., Geiger A.M., et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst 2005, 97:675-683.
7. Taplin S.H., Ichikawa L., Yood M.U., et al. Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up?. J Natl Cancer Inst 2004, 96:1518-1527.
8. Taplin S.H., Rodgers A.B. Toward improving the quality of cancer care: addressing the interfaces of primary and oncology-related subspecialty care. J Natl Cancer Inst Monogr 2010, 2010:3-10.
9. McGowan C.E., Edwards T.P., Luong M.U., et al. Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers. Clin Gastroenterol Hepatol 2015, 13:799-804.
10. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142:1264-1273.
11. Kanwal F., Kramer J.R., Ilyas J., et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014, 60:98-105.
12. Chang K.C., Wu Y.Y., Hung C.H., et al. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer 2013, 109:2481-2488.
13. Farrell G. Insulin resistance, obesity, and liver cancer. Clin Gastroenterol Hepatol 2014, 12:117-119.
14. El-Serag H.B., Hampel H., Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006, 4:369-380.
15. Wang P., Kang D., Cao W., et al. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 2012, 28:109-122.
16. Saunders D., Seidel D., Allison M., et al. Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther 2010, 31:1051-1063.
17. Schlesinger S., Aleksandrova K., Pischon T., et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer 2013, 132:645-657.
18. Zhao J., Lawless M.W. Stop feeding cancer: pro-inflammatory role of visceral adiposity in liver cancer. Cytokine 2013, 64:626-637.
19. Hassan M.M., Abdel-Wahab R., Kaseb A., et al. Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma. Gastroenterology 2015, 149:119-129.
20. White D.L., Kanwal F., El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012, 10:1342-1359.
21. Singal A.G., Manjunath H., Yopp A.C., et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 2014, 109:325-334.
22. Zenouzi R., Weismuller T.J., Hubener P., et al. Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. Clin Gastroenterol Hepatol 2014, 12:1733-1738.
23. Fattovich G., Stroffolini T., Zagni I., et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-S50.
24. Mancebo A., Gonzalez-Dieguez M.L., Cadahia V., et al. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol Hepatol 2013, 11:95-101.
25. Yang J.D., Kim W.R., Coelho R., et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011, 9:64-70.
26. Paradis V., Zalinski S., Chelbi E., et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009, 49:851-859.
27. Yasui K., Hashimoto E., Komorizono Y., et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011, 9:428-433.
28. Singal A.G., Yopp A.C., Gupta S., et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012, 5:1124-1130.
29. Blais P., Husain N., Kramer J.R., et al. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol 2015, 110:10-14.
30. Sanyal A.J. NASH: a global health problem. Hepatol Res 2011, 41:670-674.
31. Singal A.G., Mukherjee A., Elmunzer B.J., et al. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol 2013, 108:1723-1730.
32. Abu-Amara M., Cerocchi O., Malhi G., et al. The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection. Gut 2015, Epub ahead of print.
33. Wong G.L.-H., Wong V.W.-S. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol 2013, 19:6515-6522.
34. Wong V.W., Janssen H.L. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?. J Hepatol 2015, 63:722-732.
35. Lok A.S., Seeff L.B., Morgan T.R., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009, 136:138-148.
36. Singal A.G., Nehra M., Adams-Huet B., et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?. Am J Gastroenterol 2013, 108:425-432.
37. Abu Dayyeh B.K., Yang M., Fuchs B.C., et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011, 141:141-149.
38. Konerman M.A., Zhang Y., Zhu J., et al. Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data. Hepatology 2015, 61:1832-1841.
39. Singh S., Fujii L.L., Murad M.H., et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013, 11:1573-1584.
40. El-Serag H.B., Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?. Hepatology 2014, 60:1767-1775.
41. Schlesinger S., Aleksandrova K., Pischon T., et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol 2013, 24:2449-2455.
42. Welzel T.M., Graubard B.I., Quraishi S., et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 2013, 108:1314-1321.
43. Mittal S., Sada Y.H., El-Serag H.B., et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015, 13:594-601.
44. Chang M.H., Chen C.J., Lai M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997, 336:1855-1859.
45. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
46. Papatheodoridis G.V., Lampertico P., Manolakopoulos S., et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010, 53:348-356.
47. Zoutendijk R., Reijnders J.G., Zoulim F., et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013, 62:760-765.
48. Gordon S.C., Lamerato L.E., Rupp L.B., et al. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol 2014, 12:885-893.
49. Yang Y.F., Zhao W., Zhong Y.D., et al. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009, 16:265-271.
50. Sung J.J., Tsoi K.K., Wong V.W., et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008, 28:1067-1077.
51. Arase Y., Kobayashi M., Suzuki F., et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013, 57:964-973.
52. Morgan R.L., Baack B., Smith B.D., et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013, 158:329-337.
53. Davis G.L., Alter M.J., El-Serag H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513-521.
54. Kanwal F., Lok A.S., El-Serag H.B. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Clin Gastroenterol Hepatol 2013, 11:200-203.
55. Chang K.C., Hung C.H., Lu S.N., et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother 2012, 67:2766-2772.
56. Burza M.A., Pirazzi C., Maglio C., et al. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis 2012, 44:1037-1041.
57. Li J., Hernanda P.Y., Bramer W.M., et al. Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One 2015, 10:e0127967.
58. Zhang H., Gao C., Fang L., et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol 2013, 48:78-87.
59. El-Serag H.B., Johnson M.L., Hachem C., et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009, 136:1601-1608.
60. Siegel A.B., El-Serag H.B. Statins for chemoprevention of hepatocellular carcinoma: assessing the evidence. Expert Rev Gastroenterol Hepatol 2013, 7:493-495.
61. Singh S., Singh P.P., Singh A.G., et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013, 144:323-332.
62. Bravi F., Bosetti C., Tavani A., et al. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 2013, 11:1413-1421.
63. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004, 130:417-422.
64. Finberg H.J. Whither (wither?) the ultrasound specialist?. J Ultrasound Med 2004, 23:1543-1547.
65. Poustchi H., Farrell G.C., Strasser S.I., et al. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?. Hepatology 2011, 54:1998-2004.
66. Dalton-Fitzgerald E., Tiro J., Kandunoori P., et al. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2015, 13:791-798.
67. Elmunzer B.J., Singal A.G., Sussman J.B., et al. Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis. Gastrointest Endosc 2015, 81:700-709.
68. Singal A.G., Pillai A., Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014, 11:e1001624.
69. El-Serag H.B., Kramer J.R., Chen G.J., et al. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut 2011, 60:992-997.
70. Tanaka S., Kitamura T., Nakanishi K., et al. Effectiveness of periodic checkup by ultrasonography for the early diagnosis of hepatocellular carcinoma. Cancer 1990, 66:2210-2214.
71. Tong M.J., Sun H.E., Hsien C., et al. Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. Dig Dis Sci 2010, 55:826-835.
72. Trevisani F., De N.S., Rapaccini G., et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002, 97:734-744.
73. Wong G.L., Wong V.W., Tan G.M., et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int 2008, 28:79-87.
74. Yu E.W., Chie W.C., Chen T.H. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients?. Cancer J 2004, 10:317-325.
75. Singal A., Volk M.L., Waljee A., et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009, 30:37-47.
76. Santi V., Trevisani F., Gramenzi A., et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010, 53:291-297.
77. Trinchet J.C., Chaffaut C., Bourcier V., et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011, 54:1987-1997.
78. Andersson K.L., Salomon J.A., Goldie S.J., et al. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008, 6:1418-1424.
79. Arguedas M.R., Chen V.K., Eloubeidi M.A., et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003, 98:679-690.
80. Patel D., Terrault N.A., Yao F.Y., et al. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005, 3:75-84.
81. Thompson C.J., Rogers G., Hewson P., et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 2008, 98:1166-1175.
82. Pocha C., Dieperink E., McMaken K.A., et al. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography - a randomised study. Aliment Pharmacol Ther 2013, 38:303-312.
83. Mourad A., Deuffic-Burban S., Ganne-Carrie N., et al. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. Hepatology 2014, 59:1471-1481.
84. Singal A.G., Yopp A., Skinner S., et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 2012, 27:861-867.
85. Davila J.A., Henderson L., Kramer J.R., et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011, 154:85-93.
86. Singal A.G., Li X., Tiro J., et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med 2015, 128:90-97.
87. Singal A.G., Marrero J.A., Yopp A. Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw 2014, 12:375-382.
88. Singal A.G., Conjeevaram H.S., Volk M.L., et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012, 21:793-799.
89. Del P.P., Olmi S., Ciccarese F., et al. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014, 12:1927-1933.
90. Kanwal F., El-Serag H.B., Ross D. Surveillance for hepatocellular carcinoma: can we focus on the mission?. Clin Gastroenterol Hepatol 2015, 13:805-807.
91. Singal A.G., Volk M.L., Rakoski M.O., et al. Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma. J Clin Gastroenterol 2011, 45:727-732.
92. Singal A.G., Tiro J.A., Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol 2013, 11:472-477.
93. El-Serag H.B., Kanwal F. alpha-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it. Clin Gastroenterol Hepatol 2013, 11:441-443.
94. Lee E., Edward S., Singal A.G., et al. Improving screening for hepatocellular carcinoma by incorporating data on levels of alpha-fetoprotein, over time. Clin Gastroenterol Hepatol 2013, 11:437-440.
95. Gopal P., Yopp A.C., Waljee A.K., et al. Factors that affect accuracy of alpha-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014, 12:870-877.
96. El-Serag H.B., Kanwal F., Davila J.A., et al. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology 2014, 146:1249-1255.
97. Marrero J.A., Feng Z., Wang Y., et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009, 137:110-118.
98. Johnson P.J., Pirrie S.J., Cox T.F., et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev 2014, 23:144-153.
99. Lee Y.J., Lee J.M., Lee J.S., et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015, 275:97-109.
100. Massarweh N.N., Park J.O., Bruix J., et al. Diagnostic imaging and biopsy use among elderly Medicare beneficiaries with hepatocellular carcinoma. J Oncol Pract 2011, 7:155-160.
101. Barber M.D., Jack W., Dixon J.M. Diagnostic delay in breast cancer. Br J Surg 2004, 91:49-53.
102. Ramos M., Esteva M., Cabeza E., et al. Relationship of diagnostic and therapeutic delay with survival in colorectal cancer: a review. Eur J Cancer 2007, 43:2467-2478.
103. Hyder O., Dodson R.M., Nathan H., et al. Referral patterns and treatment choices for patients with hepatocellular carcinoma: a United States population-based study. J Am Coll Surg 2013, 217:896-906.
104. Patel N., Yopp A.C., Singal A.G. Diagnostic delays are common among patients with hepatocellular carcinoma. J Natl Compr Canc Netw 2015, 13:543-549.
105. Kubota K., Ina H., Okada Y., et al. Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci 2003, 48:581-586.
106. Nehra M.S., Ma Y., Clark C., et al. Use of administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol 2013, 47:e50-e54.
107. Stravitz R.T., Heuman D.M., Chand N., et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008, 121:119-126.
108. Yopp A.C., Mansour J.C., Beg M.S., et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol 2014, 21:1287-1295.
109. Aberra F.B., Essenmacher M., Fisher N., et al. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci 2013, 58:1157-1160.
110. Wigg A.J., McCormick R., Wundke, et al. Efficacy of a chronic disease management program for patients with chronic liver disease. Clin Gastroenterol Hepatol 2013, 11:850-858.
111. Beste L.A., Ioannou G.N., Yang Y., et al. Imroved surveillance for hepatocellular carcinoma with a primary-care oriented clinical reminder. Clin Gastroenterol Hepatol 2015, 13:172-179.
112. Singal A.G., Tiro J., McCallister K., et al. Outreach invitations improve hepatocellular carcinoma surveillance rates: results of a randomized controlled trial in a safety net health system September 4-6, 2015, Presented at International Liver Cancer Association, Paris, France.